ACNM Annual Meeting Track 

The ACNM 2022 Annual Meeting track will feature a robust program of cutting-edge educational content and oral presentations, highlighted by Richard Wahl, MD, FACNM, who will present the Mandell-Alavi Plenary Session. In addition, all meeting attendees are invited to attend ACNM Awards Ceremony and Banquet on Friday evening. During this event the ACNM will honor its 2022 ACNM Lifetime Achievement Award Winner, 2022 Gold Medal Award winner, present the ACNM Abstract Awards; and induct its 2022 Class of Fellows.


Friday, February 25

2:00–3:30 pm ET

ACNM Oral Abstract Presentations
Organizer: Simin Dadparvar, MD, FACNM

  • Head-To-Head Comparison of 18F-PSMA-1007 PET/CT with 68Ga-PSMA-11 PET/CT for initial staging in intermediate and high-risk prostate cancer – A Pilot Study
    Kunal Chandekar
  • Application of [ 68 Ga]PSMA PET/CT in Diagnosis and Management of Prostate Cancer Patients
    Habibollah Dadgar
  • Cyclotron vs Generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
    Juana Martinez
  • Comparison of Diagnostic Accuracy Between C-11 Methionine and F-18 Fluorocholine PET/CT in 99mTc Sestamibi Negative Hyperparathyroidism
    Muheon Shin
  • Prognostic significance of response assessment criteria in neuroendocrine tumours treated with 177Lu-DOTATATE: SSTR PET/CT based adapted PERCIST versus RECIST1.1
    Ashwani Sood
  • Changing the radiometal of a SSTR2 targeted radiopeptide conjugate impacts the in vivo profile for targeted alpha-particle therapy application
    Dijie Liu
  • Novel chelator modifications to improve in vitro and in vivo stability of 212Pb/212Bi radiopeptide drug conjugates for alpha-particle radiotherapy
    Mengshi Li
  • New Horizons of Ovarian Sentinel Node Mapping in Early Ovarian Cancer by SPECT/CT Lymphoscintigraphy
    Saeedeh Ataei-Nakhaei


3:45–5:15 pm ET

ACNM Oral Abstract Presentations
Organizer: Simin Dadparvar, MD, FACNM

  • 18F-Fluciclovine PET-MRI discrimination of recurrent intracranial metastatic disease from radiation necrosis
    Ephraim Parent
  • Role of Textural and Radiomic Analysis Parameters in Predicting Histopathological Parameters of the Tumour in Breast Cancer Patients.
    Rutuja Kote
  • Head Motion Correction and Registration Using Artificial Intelligence
    Dustin Osborne
  • Prognostic value of pretherapeutic asphericity and tumor-to-blood standard uptake ratio in patients with cervical cancer.
    Paulina Cegla
  • Liquid Gastric Emptying Study after Normal Gastric Solid Emptying – Institutional Experience in a VA Hospital Setting
    Jitesh Dhingra
  • Influence of Metabolic Tumor Burden on reference tissues’ Standardized Uptake Values in 18F-FDG PET/CT sequential Imaging
    Ahmed Kandeel
  • Prognostic Implications of Pre-ablation Stimulated Thyroglobulin: A Retrospective Analysis of 1706 Differentiated Thyroid Cancer Patients
    Emran Askari
  • Bone Scan with Tc99m-MDP, the Missing Link in the Initial Staging of Muscle-Invasive Bladder Carcinoma
    Atena Aghaee
  • Diagnostic accuracy of 99mTc-Sestamibi SPECT/CT for the characterization of solid renal lesions
    Ashwin Singh Parihar

5:30–6:30 pm ET

ACNM Oral Abstract Presentations
Organizer: Simin Dadparvar, MD, FACNM

  • Diagnostic performance of 68Ga-DOTA labeled somatostatin analog PET/CT over conventional imaging  in patients with metastatic and SDHx mutation paraganglioma and pheochromocytoma
    Surekha Yadav
  • Utility of 18F FDG PETCT in early diagnosis and management of seronegative autoimmune encephalitis patients: An experience from a tertiary care centre
    Ram Kumar
  • Evaluation of Interim 68Ga-Dotatate PET after Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
    Heying Duan
  • Can myocardial flow reserve and stress myocardial blood flow predict major adverse cardiac events in diabetic patients asymptomatic for coronary artery disease?
    Tinu Lukose
  • Routine Use of Lateral Vertebral Assessment with DXA Scan for Detection of Silent but Debilitating Vertebral Fractures
    Sana Gill
  • Emission-based attenuation correction for Brain PET imaging using conditional generative adversarial networks
    Jonathan Fisher
Saturday, February 26

10:00–11:30 am ET

Theranostic Nuclear Medicine is Coming of Age!
Sponsored by the ACNM
Organizers/Moderators:
Mark Tulchinsky, MD, FACNM, FSNMMI
Lilja B. Solnes, MD, MBA
 
Session Objectives
  • Discuss reasons for decline of I-131 therapy for hyperthyroidism.
  • Discuss main changes needed in the specialty practice and policy to ensure sustainability of Theranostic Nuclear Medicine.
  • List practical changes desirable to actualize in individual practice sites to strengthen the specialty's leadership in Theranostic space.

Presentations Include:

  • Learning from the Original Theranostic Nuclear Medicine Disease-Radiopharmaceuticals Couple
    Mark Tulchinsky, MD, FACNM, FSNMMI
  • The Arc of Molecular Imaging Bends Toward Theranostic Nuclear Medicine!   
    Martin G. Pomper, MD, PhD 


11:45 am–1:15 pm ET

Mandell-Alavi Plenary Lectureship
Sponsored by the ACNM
Organizer/Moderator: Gary Ulaner, MD, PhD, FACNM

Session Objectives

  • Discuss the important history of nuclear medicine
  • Examine future opportunities in Theranostics
  • Identify areas where personal contributions can enhance the field of nuclear medicine

Presentations Include:

  • Introduction of Dr. Richard Wahl
    Gary Ulaner, MD, PhD, FACNM
  • Precision Quantitative Nuclear Oncology
    Richard Wahl, MD, FACNM
  • Panel Discussion & Q/A w/ Speakers


2:30–4:00 pm ET

Y-90 Therapy
Sponsored by the ACNM
Organizer: Bruce J. Barron, MD, MHA, FACNM
Moderator: Saima Muzahir, MBBS, MD

Session Objectives

  • Examine difference between glass and resin beads
  • Determine how to calculate dose to be delivered
  • Discuss how to deal with unexpected events

Presentations Include:

  • Y-90 Radioablation Therapy
    Bruce J. Barron, MD, MHA, FACNM
  • Y-90 Therasphere Therapy
    Saima Muzahir, MBBS, MD
  • Panel Discussion & Q/A w/ Speakers


Metastatic Thyroid Cancer

Sponsored by the ACNM
Organizer: Mark Tulchinsky, MD, FACNM, FSNMMI
Moderator: Bruce J. Barron, MD, MHA, FACNM

Session Objectives

  • Describe practical composition of Thyroid Tumor Board and Nuclear Medicine specialists' role.
  • Describe practical role of Theranostic Nuclear Medicine to the management of DTC.
  • Describe practical applications of Theranostic Nuclear Medicine principles in the selection of administered I-131 activity.

Presentations Include:

  • Theranostic Nuclear Medicine Paradigm for Optimal Management of Metastatic Differentiated Thyroid Cancer
    Mark Tulchinsky, MD, FACNM, FSNMMI


4:15–5:45 pm ET

Nuclear Medicine Theranostics in Neuroendocrine Tumors: Taming the Zebras
Sponsored by the ACNM
Organizer: Ashwin Singh Parihar, MBBS, MD
Moderator: Bital Savir-Baruch, MD
 
Session Objectives

  • Discuss the imaging-guided patient selection for Peptide receptor radionuclide therapy (PRRT)
  • Describe the practical aspects of performing PRRT
  • Discuss the latest developments around PRRT
     

Presentations Include:

  • Imaging and Patient Selection for PRRT
    Ashwin Singh Parihar, MBBS, MD
  • The Principles and Practice of PRRT
    Erik Mittra, MD, PhD
  • Improving on Current Practice: PRRT Moving Forward
    Thomas A. Hope, MD
  • Case Discussion
    Amir Iravani, MD, FRACP


Sunday, February 27

10:00–11:30 am ET

Estrogen Receptor Targeted PET with 18F-Fluoroestradiol for Patients with Breast Cancer
Sponsored by the ACNM
Organizer: Gary Ulaner, MD
Moderator: Bital Savir-Baruch, MD; Hannah M. Linden, MD

Session Objectives

  • Examine the mechanisms and principles behind 18FfluoroestradiolDescribe concept of oligometastatic in prostate cancer
  • Discuss clinical applications of 18-fluoroestradiol
  • Develop an approach for interpretation of 18Ffluoroestradiol


Presentations Include:

  • Estrogen Receptor-targeted imaging: Mechanisms and Principles
    Hannah M. Linden, MD
  • Estrogen Receptor-targeted imaging: Interpretation and Applications
    Gary Ulaner, MD, PhD, FACNM


11:45 am–1:15 pm ET

Theranostics Around the World
Sponsored by the ACNM
Organizer: Simin Dadparvar, MD, FACNM, FACR, FSNMMI
Moderator: Alan K. Klitzke, MD, FACNM, FACR

Session Objectives

  • Teach applications of theranostics in treatment of liver tumors and neuroendocrine tumors
  • Discuss how to learn from our current mistakes and the future of theranostics
  • Evaluate the pros and cons for each modality of therapy


Presentations Include:

  • Intra-arterial Y-90 microsphere therapy in the Era of Theranostics: Personalized Radioembolization
    Fani Murat Bozkurt, MD
  • Theranostics in Gastroentrohepatic neuroendocrine tumors (GEP- NETS): Basic Principals and Clinical
    Applications
    Aakif Ullah Khan, MBBS, FCRS
  • Future of Theranostics
    Richard NJ Graham, MA, BM, BCh, FRCR
  • Expert Panel

 

2:30–4:00 pm ET

The Diagnosis and Management of Prostate Cancer in Nuclear Medicine
Sponsored by the ACNM
Organizer: Bital Savir-Baruch, MD
Moderator: Alan K. Klitzke, MD, FACNM, FACR

Session Objectives

  • Discuss the use of FDA-approved PET tracers in prostate cancer imaging
  • Discuss Learn the concept of oligometastatic in prostate cancer
  • Examine the introduction of metastatic prostate cancer therapy


Presentations Include:

  • Prostate Cancer Imaging using FDA Approved Fluciclovine and PSMA PET Tracers
    Bital Savir-Baruch, MD
  • The Concept of Oligometastatic Disease and Prostate Cancer
    Hossein Jadvar, MD, PhD, FACNM, FSNMMI
  • Incorporation of 177Lu-PSMA-617 Into the Management of Prostate Cancer - Review of the VISION Trial
    Jeremie Calais, MD
  • Expert Panel

4:15–5:45 pm ET

Practical Considerations for Initiating an I-131 MIBG Therapy Program 
Sponsored by the ACNM
Organizer: Simin Dadparvar, MD, FACNM, FACR, FSNMMI
Moderator: Simin Dadparvar, MD, FACNM, FACR, FSNMMI

Session Objectives

  • Determine the patient criteria's eligibility for I131-MIBG therapy
  • Examine nuts and bolts of I-123 MIBG diagnostic studies
  • Evaluate the patients prior to consideration for therapy


Presentations Include:

  • Practical Considerations for Initiating an I-131 MIBG Therapy Program  
    Daniel Pryma, MD


5:00–6:00 pm ET

ACNM Annual Flipped Learning Session with a Focus on Theranostics   
Sponsored by the ACNM
Organizer/Speakers: Twyla Bartel, DO, MBA, FACNM, FSNMMI; Tracy Yarbrough, MD, PhD, MEd, FACNM
Moderator: Mickaila Johnson, MD, FACNM

Session Objectives
  • Actively participate in a 3-step mechanism to reinforce and aid in retention of learning around theranostics.
  • Understand the imaging (functional and anatomic) and therapy available for nuclear medicine professionals currently.
  • Review specific cases related to theranostics that were presented at the entire ACNM meeting.